IndieBio

Canaery is building a neural interface for analyzing an object’s scent fingerprint to identify dangerous compounds at places like ports and inspection points without (or in addition to) x-rays or cameras.

ClimateCrop technologies allow plants to store more carbon and energy, resulting in increased yields in biomass or fruit states. Founded in 2021 and is based in Ness Ziona.

ClimateCrop technologies allow plants to store more carbon and energy, resulting in increased yields in biomass or fruit states. Founded in 2021 and is based in Ness Ziona.

ClimateCrop technologies allow plants to store more carbon and energy, resulting in increased yields in biomass or fruit states. Founded in 2021 and is based in Ness Ziona.

Indee Labs is developing hardware for gene delivery. Our hardware is uniquely positioned for the efficient development and scalable manufacture of gene-modified cell therapies such as chimeric antigen receptor T cells. The technology is being developed with the help of the Australian National Fabrication Facility. We are alumni of NSW Health, IndieBio, Y Combinator and MBC Biolabs (née QB3@953). We are opening up an office in Sydney and have lab space at Bonneville Labs in Berkeley.

JointechLabs, Inc. is a company focused on enhancing access to cell-based therapies for healthcare providers and patients. Based in Mount Prospect, Illinois, the company has developed the Mini-Stem System, a closed disposable kit designed for the processing and extraction of stromal vascular cell fractions from human tissue. This innovative medical device allows for the efficient preparation of high-quality injectable fat grafts and fat-derived stem cells, facilitating on-site access to optimized adipose-derived stromal cells (ADSC). By streamlining the process of individualized cell and tissue-based therapies, JointechLabs aims to make these advanced treatments more accessible and cost-effective for use in hospitals, clinics, and local medical offices. Since its incorporation in 2012, the company has been dedicated to improving the efficacy and availability of cell therapies in clinical settings.

Stämm Biotech, founded in 2014 and based in San Francisco, California, specializes in innovative biomanufacturing solutions for the life sciences sector. The company has developed a novel bioproduction system that integrates microfluidics, electroporation, and robotics to address the challenges of scaling in the biotech industry. Stämm's flagship product, the Bioprocessor, is an all-in-one, plug-and-play desktop unit that significantly enhances productivity, being at least 70 times more efficient than conventional bioreactors. Additionally, Stämm offers a suite of products including an automated continuous batch system for microbial growth, tools for tracking biological variations, and systems for monitoring microorganisms to convert data into actionable insights. This technological advancement positions Stämm to unlock a substantial market opportunity in biomanufacturing over the next decade.

Gaia Laboratories revolutionizes cell production, creating powerful solutions for the defining challenges of time. The founding principles behind Gaia Laboratories are to combat climate change, enable space-food, and make cell therapy accessible to everyone.

Developing technology to fight mosquitoes with mosquitoes.

Canaery is building a neural interface for analyzing an object’s scent fingerprint to identify dangerous compounds at places like ports and inspection points without (or in addition to) x-rays or cameras.

Canaery is building a neural interface for analyzing an object’s scent fingerprint to identify dangerous compounds at places like ports and inspection points without (or in addition to) x-rays or cameras.

Operator of a biotechnology company intended to help people live as long, and well, as possible by rapidly developing advanced longevity technologies. The company's technology biologically integrates with a host wearer for bi-directional information exchange rather than relying on hardware probes, enabling patients to get their personal stem cells.

Operator of a biotechnology company intended to help people live as long, and well, as possible by rapidly developing advanced longevity technologies. The company's technology biologically integrates with a host wearer for bi-directional information exchange rather than relying on hardware probes, enabling patients to get their personal stem cells.

BiomeSense is revolutionizing human microbiome research by developing novel technologies to enable investigators to collect, store, and analyze the daily microbiome profiles of clinical trial participants in a low-cost, scalable way. By enabling daily profiling, the platform allows investigators the unprecedented ability to tie microbiome changes directly to clinical outcomes in real time, dramatically increasing the research discovery potential.

Liberum Biotech is a biotechnology company focused on advancing protein manufacturing through proprietary molecular and hardware technologies. Its platform facilitates the rapid production of enzymes, therapeutics, and laboratory reagents, enabling clients to enhance speed and scalability while significantly reducing costs. By leveraging its innovative protein synthesizers, Liberum aims to democratize access to synthetic biology, ultimately transforming existing biologics manufacturing practices and making these technologies more accessible to a broader range of users.

Developing technology to fight mosquitoes with mosquitoes.

Developing technology to fight mosquitoes with mosquitoes.

Developing hardware for manufacturing next-generation medicines.

Developing hardware for manufacturing next-generation medicines.

Catalog Technologies Inc. is a Boston-based company that specializes in a DNA-based platform designed for digital data storage and computation. Founded in 2016, Catalog's innovative platform encodes digital information into DNA, providing a new approach to long-term data archiving. This method not only enhances data storage capacity but also offers a cost-effective solution for managing vast amounts of information. By integrating advanced synthetic biology technologies, Catalog aims to revolutionize the way digital data is archived and processed, making DNA a viable medium for future data storage needs.

Electro-Active Technologies LLC, founded in 2017 and based in Knoxville, Tennessee, specializes in developing modular systems that convert organic waste into renewable hydrogen. The company employs advanced microbial and electrochemical processes to effectively degrade organic materials, generating electrons and protons that facilitate hydrogen production. By transforming waste into valuable renewable products, Electro-Active Technologies aims to enhance sustainability for businesses and communities, allowing them to derive additional value from their waste resources.

Operator of a biotechnology company intended to help people live as long, and well, as possible by rapidly developing advanced longevity technologies. The company's technology biologically integrates with a host wearer for bi-directional information exchange rather than relying on hardware probes, enabling patients to get their personal stem cells.

Developing hardware for manufacturing next-generation medicines.

Stämm Biotech, founded in 2014 and based in San Francisco, California, specializes in innovative biomanufacturing solutions for the life sciences sector. The company has developed a novel bioproduction system that integrates microfluidics, electroporation, and robotics to address the challenges of scaling in the biotech industry. Stämm's flagship product, the Bioprocessor, is an all-in-one, plug-and-play desktop unit that significantly enhances productivity, being at least 70 times more efficient than conventional bioreactors. Additionally, Stämm offers a suite of products including an automated continuous batch system for microbial growth, tools for tracking biological variations, and systems for monitoring microorganisms to convert data into actionable insights. This technological advancement positions Stämm to unlock a substantial market opportunity in biomanufacturing over the next decade.

Electro-Active Technologies LLC, founded in 2017 and based in Knoxville, Tennessee, specializes in developing modular systems that convert organic waste into renewable hydrogen. The company employs advanced microbial and electrochemical processes to effectively degrade organic materials, generating electrons and protons that facilitate hydrogen production. By transforming waste into valuable renewable products, Electro-Active Technologies aims to enhance sustainability for businesses and communities, allowing them to derive additional value from their waste resources.

BiomeSense is revolutionizing human microbiome research by developing novel technologies to enable investigators to collect, store, and analyze the daily microbiome profiles of clinical trial participants in a low-cost, scalable way. By enabling daily profiling, the platform allows investigators the unprecedented ability to tie microbiome changes directly to clinical outcomes in real time, dramatically increasing the research discovery potential.

Calyx is a material science and Internet of Things (IoT) platform company that leverages biological principles to develop low-cost and highly accurate sensors for real-time detection and analysis of air chemicals. Founded in 2014 and rebranded from BioInspira in 2019, Calyx serves various sectors, including industrial safety, healthcare, transportation, and food markets. The company's innovative sensor technology is designed to enhance monitoring applications, including health and air quality assessments, along with ensuring safety in natural gas infrastructure. Based in Berkeley, California, Calyx is focused on providing solutions that improve safety and efficiency across multiple industries.

Stämm Biotech, founded in 2014 and based in San Francisco, California, specializes in innovative biomanufacturing solutions for the life sciences sector. The company has developed a novel bioproduction system that integrates microfluidics, electroporation, and robotics to address the challenges of scaling in the biotech industry. Stämm's flagship product, the Bioprocessor, is an all-in-one, plug-and-play desktop unit that significantly enhances productivity, being at least 70 times more efficient than conventional bioreactors. Additionally, Stämm offers a suite of products including an automated continuous batch system for microbial growth, tools for tracking biological variations, and systems for monitoring microorganisms to convert data into actionable insights. This technological advancement positions Stämm to unlock a substantial market opportunity in biomanufacturing over the next decade.

JointechLabs, Inc. is a company focused on enhancing access to cell-based therapies for healthcare providers and patients. Based in Mount Prospect, Illinois, the company has developed the Mini-Stem System, a closed disposable kit designed for the processing and extraction of stromal vascular cell fractions from human tissue. This innovative medical device allows for the efficient preparation of high-quality injectable fat grafts and fat-derived stem cells, facilitating on-site access to optimized adipose-derived stromal cells (ADSC). By streamlining the process of individualized cell and tissue-based therapies, JointechLabs aims to make these advanced treatments more accessible and cost-effective for use in hospitals, clinics, and local medical offices. Since its incorporation in 2012, the company has been dedicated to improving the efficacy and availability of cell therapies in clinical settings.

Catalog Technologies Inc. is a Boston-based company that specializes in a DNA-based platform designed for digital data storage and computation. Founded in 2016, Catalog's innovative platform encodes digital information into DNA, providing a new approach to long-term data archiving. This method not only enhances data storage capacity but also offers a cost-effective solution for managing vast amounts of information. By integrating advanced synthetic biology technologies, Catalog aims to revolutionize the way digital data is archived and processed, making DNA a viable medium for future data storage needs.

Indee Labs is developing hardware for gene delivery. Our hardware is uniquely positioned for the efficient development and scalable manufacture of gene-modified cell therapies such as chimeric antigen receptor T cells. The technology is being developed with the help of the Australian National Fabrication Facility. We are alumni of NSW Health, IndieBio, Y Combinator and MBC Biolabs (née QB3@953). We are opening up an office in Sydney and have lab space at Bonneville Labs in Berkeley.

Orphidia Ltd is focused on developing a portable blood diagnostic platform that enables rapid laboratory testing. The company has created a device capable of conducting 40 common blood tests from a single drop of blood, delivering results in just 20 minutes. Incorporated in 2013 and headquartered in London, United Kingdom, Orphidia aims to enhance patient care by making laboratory tests more accessible and efficient.

Amino Labs Inc. is a biotechnology company founded in 2015 and based in Canada that focuses on making genetic engineering accessible to a wider audience. The company has developed an intuitive bioengineering mini-lab, a compact continuous bioreactor designed to facilitate bacterial transformations and the continuous growth of various cultures. This user-friendly equipment allows individuals, including those as young as eight, to experiment with genetic engineering, fostering a new generation of bioengineers. The bioreactor serves as a countertop-sized laboratory, providing educational opportunities to learn about DNA, genes, and cell theory, while enabling users to create a diverse range of products, including fragrances, flavors, materials, and medicines. By democratizing access to biotechnology, Amino Labs aims to contribute to personalized manufacturing and address significant global challenges related to food, fuel, and medicine.

Orphidia Ltd is focused on developing a portable blood diagnostic platform that enables rapid laboratory testing. The company has created a device capable of conducting 40 common blood tests from a single drop of blood, delivering results in just 20 minutes. Incorporated in 2013 and headquartered in London, United Kingdom, Orphidia aims to enhance patient care by making laboratory tests more accessible and efficient.

At DtoR they have developed the PCR of gene expression—a disruptive technology that will revolutionize the tools used to “tune” protein production in any organism. In one step, and for any cell type, they can identify all of the switches regulating expression of the genome, as well as how active they are. They can also rapidly evolve or synthesize new switches to adapt to any application. Applications developed using their platform will lead to improved product yields in bioreactors, engineered specialty crops, optimized cancer therapeutics, and much more. The possibilities are limited only by their partners' imaginations.

Developer of invitro diagnostics technology designed for accurate and accessible testing products. The company's platform utilizes novel technologies to create mobile, point-of-care, and self-testing products and devices with the ability to accurately, quickly, and cost-effectively conduct testing, enabling people to put healthcare information directly into their hands to improve their quality of life.

They are building a flexible and friendly robotic lab assistant to help scientists be scientists. They’re aBioBot, and we’re here to usher in an ergonomic laboratory and unleash a revolution.

Developer of invitro diagnostics technology designed for accurate and accessible testing products. The company's platform utilizes novel technologies to create mobile, point-of-care, and self-testing products and devices with the ability to accurately, quickly, and cost-effectively conduct testing, enabling people to put healthcare information directly into their hands to improve their quality of life.